| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. | Director | Common Stock | 1,460,000 | $2,000,200 | $1.37 | 21 Oct 2024 | Indirect |
| Inhibikase Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 108,176 | 30 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | 30 Jun 2025 | 1 | $0 | 4 | Director | 02 Jul 2025, 19:38 |
| IKT | Inhibikase Therapeutics, Inc. | 14 Feb 2025 | 2 | $0 | 4 | Director | 19 Feb 2025, 20:18 |
| IKT | Inhibikase Therapeutics, Inc. | 21 Oct 2024 | 2 | +$2,000,200 | 4 | Director | 23 Oct 2024, 19:53 |
| IKT | Inhibikase Therapeutics, Inc. | 21 Oct 2024 | 0 | $0 | 3 | Director | 23 Oct 2024, 19:35 |